84-1195-74　EDIL3 (Integrin-binding Protein DEL1, DEL1, Developmentally-regulated Endothelial Cell Locus 1 Protein, EGF-like Repeat And Discoidin I-like Domain-containing Protein 3) 100ug　E2204-30C

特徴

• EGF-like repeat and discoidin I-like domain-containing protein 3 (EDIL3; also Del-1 and integrin-binding DEL1) is a 52kD extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development.
• Human EDIL3 is synthesized as a precursor with a 16aa signal sequence and a 464aa mature chain.
• The mature chain is composed of three epidermal growth factor (EGF) repeats and two discoidin-I-like domains.
• The second EGF repeat contains an RGD motif.
• Splicing variants produce two isoforms for human EDIL3.
• Isoform 2 has an A->G substitution at aa66 and a deletion of aa67-76 found in isoform 1.
• Mature human EDIL3 shares 96aa sequence identity with mature mouse EDIL3.
• The RGD motif of EDIL3 binds av b5 integrin, which, in turn, leads to increased angiogenic transcription factor HoxD3 expression.
• HoxD3activates av b3 and uPA, resulting in the transformation of resting endothelial cells to an angiogenic state.
• EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues.
• It has been found, however, re-expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis.
• EDIL3 promotes adherence and migration of endothelial cells, and acts as an endothelial cell survival agent through upregulation of Bcl-2 expression.
• Exogenous application of EDIL3 has been demonstrated to augment angiogenesis and improve blood flow and tissue function in murine models of hind-limb ischemia, cardiac ischemia and cerebral ischemia.
• EDIL3 has also been shown to be an endogenous inhibitor of inflammatory cell recruitment by interfering with the integrin LFA-1-dependent leukocyte-endothelial adhesion.
• Applications:Suitable for use in Western Blot and Immunocytochemistry.
• Other applications not tested.
• Recommended Dilution:Western Blot: 1ug/ml SH­SY5Y human neuroblastoma cell line, MDA­MB­231 human breast cancer cell line, HFL1 human fetal lung fibroblast cell line, and MRC­5 human embryonic lung fibroblast cell lineImmunocytochemistry: 5-15ug/ml immersion fixed MDA­MB­231 human breast cancer cell lineOptimal dilutions to be determined by the researcher.
• Storage and Stability:Lyophilized and reconstituted products are stable for 12 months after receipt at -20°C.
• Reconstitute with sterile PBS.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Further dilutions can be made in assay buffer.